Trials / Completed
CompletedNCT00973076
Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055
A Phase I, Open Label, Single-centre Study to Assess the Safety and Tolerability of the Tor Kinase Inhibitor AZD8055 Administered Orally to Japanese Patients With Advanced Solid Tumours
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective is to assess the safety and tolerability of AZD8055 in Japanese patients with advanced solid tumours.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD8055 | Tablets, orally administered, twice daily |
Timeline
- Start date
- 2009-08-01
- Primary completion
- 2010-12-01
- Completion
- 2010-12-01
- First posted
- 2009-09-09
- Last updated
- 2011-06-15
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00973076. Inclusion in this directory is not an endorsement.